An acute lymphoblastic leukemia occurring during childhood. The majority of cases are B-acute lymphoblastic leukemias. Approximately 15% of the cases are T-acute lymphoblastic leukemias.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation surrounding childhood acute lymphoblastic leukemia is limited due to its relatively rare occurrence in the pediatric population, which restricts the scope of systematic clinical studies. Additionally, the complexity of the disease and the variability in clinical presentation contribute to the challenges in establishing comprehensive documentation. Ongoing research efforts aim to enhance our understanding of this condition.
To navigate childhood acute lymphoblastic leukemia, consider consulting a pediatric oncologist with experience in treating leukemia in children. It may also be beneficial to seek out a genetic counselor to discuss any potential genetic factors or family implications, even though no specific genetic basis has been established. You can find resources at the National Society of Genetic Counselors' website: [findageneticcounselor.com](https://www.findageneticcounselor.com). Additionally, inquire about participation in clinical trials as a way to access cutting-edge therapies.
There are currently 154 active clinical trials focused on childhood acute lymphoblastic leukemia, exploring various treatment options and therapies. Some of the FDA-approved orphan drugs include tisagenlecleucel, asparaginase erwinia chrysanthemi, and brexucabtagene autoleucel, among others. Additionally, several drugs are designated and in development, such as CAR T-cell therapies targeting CD19 and CD7. For more information on clinical trials, you can visit [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=childhood%20acute%20lymphoblastic%20leukemia).
Actionable guidance for navigating care for childhood acute lymphoblastic leukemia
To navigate childhood acute lymphoblastic leukemia, consider consulting a pediatric oncologist with experience in treating leukemia in children. It may also be beneficial to seek out a genetic counselor to discuss any potential genetic factors or family implications, even though no specific genetic basis has been established. You can find resources at the National Society of Genetic Counselors' website: [findageneticcounselor.com](https://www.findageneticcounselor.com). Additionally, inquire about participation in clinical trials as a way to access cutting-edge therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning childhood acute lymphoblastic leukemia
Updated Feb 7, 2026
The discussion highlights the transformative impact of CAR T therapy, specifically obe-cel, on the treatment of acute lymphoblastic leukemia (ALL). Clinical trial data suggests improved efficacy and safety outcomes, emphasizing the need for oncology pharmacists to manage toxicity and coordinate care effectively.
Real-world data confirms that inotuzumab ozogamicin significantly improves remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), with a 51.7% overall survival rate. The study highlights a 71.4% MRD-negative status in patients, facilitating further treatment options like ASCT or CAR T.